PAHPathways.com Terms and Conditions

PAH Pathways Interactive Resource Locator

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more »

PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE ACCESSING ANY PAGES IN THIS WEBSITE.
By using or accessing this website you signify acknowledgment and assent to the conditions of use set forth below. If you do not agree to these terms and conditions, please do not use this website. Actelion Pharmaceuticals US, Inc. (Actelion) can revise these terms and conditions at any time by updating this posting, and your use afterwards signifies your acceptance of the changed terms. Please check these terms and conditions periodically for changes.

Actelion is providing the material on this site for your personal information only. In connection with viewing and using this website you are permitted to temporarily download one copy of the materials posted on this website onto a single computer for your personal, non-commercial use only. Redistribution, retransmission, republication or commercial exploitation of the contents of this website are expressly prohibited without the prior express written consent of Actelion. All rights not expressly granted herein are reserved. Downloading of any information, content or images from this website does not transfer any right or ownership of such information, content or images to you, and such information, content or images may be used solely in accordance with these terms and conditions. You may not mirror or archive any part of this site or any material contained on this site on any server or computer without Actelion's prior written permission. The content of this website is owned or controlled by Actelion and is protected under applicable copyright and trademark laws. All copyright and other proprietary notices contained in downloadable materials must be retained.

Medical Information

This website may contain information relating to various medical conditions and their treatments. Such information is provided for informational purposes only and is not meant to be a substitute for the advice of a physician. You should not use this information for diagnosing or treating a health problem or disease. In order for you to make informed healthcare decisions, you should always consult with your physician for your personal medical needs. Neither Actelion, nor its agents, affiliates, partners, or licensors are providing the materials to you for the purpose of giving you medical advice. You should not rely on the materials in deciding on a treatment plan, drug usage, or any other medical advice regarding the materials, and Actelion and its licensors strongly urge that you consult with a physician in connection with any and all treatment options that may be available to you.

Jurisdiction

Although it is accessible worldwide, this website and its content are intended only for residents of the United States only. Nothing in this website should be interpreted as a promotion or solicitation for any product or of any nature that is not authorized by the laws and regulations of the country where you are located.

These terms and conditions shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any principles of conflicts of law. You and Actelion irrevocably consent to the exclusive jurisdiction of the courts located in Delaware in connection with any action arising out of or related to these terms and conditions or their subject matter. You and Actelion waive any objection based on lack of personal jurisdiction, place of residence, improper venue or forum non-conveniens in any such action.

Privacy

Please see our Privacy Policy for information regarding the collection and use of personal information from this website.

Severability

If any provision of these terms and conditions shall be deemed unlawful, void, or for any reason unenforceable, then that provision shall be deemed severable from the remaining terms and conditions and shall not affect the validity and enforceability of any remaining provisions.

Securities and Investment

This website and the information contained or referred to herein do not constitute an offer or a solicitation of an offer for the purchase or sale of any securities.

Links to Other Sites

As a convenience, from time to time www.pahpathways.com may provide certain links or references to other websites that we think may be useful or of interest to you. Actelion neither controls, endorses, promotes nor has any affiliation with any other website unless expressly stated herein or on such website. Actelion therefore has no responsibility for the content, accuracy or any other aspect of the information contained on such linked websites. Actelion will not be liable for any damages or injury arising from your access to such websites or content.

E-mailing Content

As a convenience, Actelion also allows you to e-mail certain content from the website to friends who may find such content useful or interesting. Actelion does not monitor or control such e-mails and is not responsible for any content, accuracy or any other aspect of any information you include in the body of such e-mails. Actelion will not be liable for any damages or injury arising from the use of such e-mails or any information contained in the body of such e-mails.

Warranty

ACTELION MAKES NO REPRESENTATIONS OR WARRANTIES AS TO THE TIMELINESS, AVAILABILITY, ACCURACY OR COMPLETENESS OF ANY INFORMATION CONTAINED IN THIS WEBSITE. LIKE ANY PRINTED MATERIALS, THE INFORMATION PROVIDED IN THIS WEBSITE MAY BECOME OUTDATED OVER TIME. ACTELION UNDERTAKES NO OBLIGATION TO CORRECT OR UPDATE ANY CONTENT OR INFORMATION ON THIS WEBSITE. ACTELION MAY MAKE IMPROVEMENTS AND/OR CHANGES IN THE PRODUCTS AND/OR SERVICES DESCRIBED IN THIS CONTENT AND INFORMATION AT ANY TIME WITHOUT NOTICE, AND RESERVES THE RIGHT TO ALTER OR DELETE CONTENT AND INFORMATION ON THE WEBSITE AT ANY TIME. ALL INFORMATION ON THIS WEBSITE IS PROVIDED "AS IS," WITHOUT ANY WARRANTIES, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, ALL OF WHICH ARE EXPRESSLY DISCLAIMED.

NEITHER ACTELION, NOR ANY AFFILIATE, NOR ANY PARTY INVOLVED IN CREATING, PRODUCING OR DELIVERING THIS WEBSITE WILL BE LIABLE FOR YOUR USE OF OR RELIANCE ON INFORMATION CONTAINED ON THIS WEBSITE UNDER ANY CIRCUMSTANCES, INCLUDING NEGLIGENCE. NEITHER SHALL ACTELION BE LIABLE FOR ANY INJURY OR ANY DIRECT, INDIRECT, SPECIAL, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER DAMAGES ARISING OUT OF ACCESS TO, USE OF OR INABILITY TO USE WWW.PAHPATHWAYS.COM, THE CONTENT THEREOF OR MATERIALS ON THIS WEBSITE, EVEN IF ACTELION IS INFORMED OF THE POSSIBILITY OF SUCH DAMAGES. APPLICABLE LAW MAY NOT ALLOW THE LIMITATION OR EXCLUSION OF LIABILITY OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION MAY NOT APPLY TO YOU. IN NO EVENT SHALL ACTELION'S TOTAL LIABILITY TO YOU FOR ALL DAMAGES, LOSSES AND CAUSES OF ACTION ARISING FROM OR RELATED TO THIS WEBSITE (WHETHER IN CONTRACT, TORT OR OTHERWISE) EXCEED THE AMOUNT PAID BY YOU, IF ANY, FOR ACCESSING THIS WEBSITE.

Trademarks, Images and Copyrights

Nothing on this website shall be construed as conferring any license under any intellectual property right, including any right in the nature of trademark or copyright, of Actelion or any third party, whether by estoppel, implication, or otherwise. All brands and names are the property of their respective owners. All product names, trademarks, logos and service marks (collectively referred to as "Trademarks") displayed on this website are the property of Actelion, its respective affiliates, related companies, licensors or business partners. The trademarks, service marks, trade names, trade dress, and products on this website are protected in the United States and internationally. The use or misuse of these trademarks or any other materials, except as permitted herein, is expressly prohibited and may be in violation of the laws of copyright, trademark, privacy, publicity, slander, libel, and communications. Please be advised that Actelion (and its respective affiliates) actively and aggressively enforce intellectual property rights to the fullest extent of the law. Images of people or places displayed on this website are either the property of Actelion, or used with permission by the copyright owner. The use of these images by you is prohibited unless specifically permitted by the terms and conditions of this website. Unauthorized use of the images may violate the laws of copyright, trademark, privacy, publicity, and communications.

Actelion is pleased to hear from its customers, however we do not accept or consider any creative ideas, suggestions or other materials related to products, services or marketing unless we have specifically requested them. Therefore, please do not send us any original creative materials such as product ideas or suggestions. Anything you disclose or offer to us by or through this website (a "Disclosure"), including e-mails to Actelion, shall be deemed and shall remain the property of Actelion. Any such Disclosure is provided on a non-confidential basis with no obligation on our part to keep such information secret. Actelion is free to use, for any purpose whatsoever, any Disclosure, including but not limited to publishing, or developing, manufacturing, and marketing products using such information. You hereby release Actelion from any liability under any legal theory in connection with the use, modification, sale, or disclosure of any Disclosure. By uploading or otherwise providing any Disclosure to this website or Actelion, you hereby grant Actelion, to the extent you retain any rights, the unlimited, perpetual right to reuse, redistribute, modify and create derivative works from such Disclosure for any purpose and in any media without compensation, and you warrant that all "moral rights" in uploaded materials have been waived.

Date Last Modified:
These Terms and Conditions were last modified on August 30, 2011.

Actelion Contact Information:

Please contact Actelion with any questions or comments about these Terms and Conditions, your personal information, our third-party disclosure practices, or your consent choices at:

Actelion Pharmaceuticals US, Inc.
c/o Privacy Officer
5000 Shoreline Court, Suite 200
San Francisco, CA 94080

Copyright © 2012 Actelion Pharmaceuticals US, Inc. All rights reserved. The text, images, graphics, sound files, and their arrangement on this website are all subject to copyright and other intellectual property protection. These objects may not be copied for commercial use or distribution, nor may these objects be modified or posted to other sites.

Tracleer Indication:

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital systemic-to-pulmonary shunts (18%).

Considerations for use
Patients with WHO class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of liver injury in WHO class II patients, which may preclude future use as their disease progresses.

Tracleer Important Safety Information:

Because of the risks of liver injury and birth defects, Tracleer may be prescribed and dispensed only through the Tracleer Access Program (T.A.P.), a restricted distribution program, by calling 1-866-228-3546. Only prescribers and pharmacies registered with T.A.P. may prescribe and distribute Tracleer. Tracleer may be dispensed only to patients who are enrolled in and meet all conditions of T.A.P.

Liver injury
Elevations of liver aminotransferases (ALT, AST) and liver failure have been reported with Tracleer. In a setting of close monitoring, rare cases of liver failure and unexplained hepatic cirrhosis were observed after prolonged treatment. In general, avoid using Tracleer in patients with elevated aminotransferases (>3 x ULN). Measure liver aminotransferases prior to initiation of treatment and then monthly. Discontinue Tracleer if aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin ≥2 x ULN.

Teratogenicity
Based on animal data, Tracleer is likely to cause major birth defects if used during pregnancy. Exclude pregnancy before and during treatment. To prevent pregnancy, females of childbearing potential must use 2 reliable forms of contraception during treatment and for 1 month after stopping Tracleer unless the patient has a tubal sterilization or Copper T 380A IUD or LNg 20-IUS inserted, in which case no other contraception is needed. Monthly pregnancy tests should be obtained.

CONTRAINDICATIONS
Tracleer is contraindicated with cyclosporine A, glyburide, in females who are or may become pregnant, or in patients who are hypersensitive to bosentan or any component of Tracleer.

WARNINGS AND PRECAUTIONS
In clinical trials, Tracleer caused ALT/AST elevations (>3 x ULN) in 11% of patients accompanied by elevated bilirubin in a few cases. The combination of hepatocellular injury (increases in aminotransferases of >3 x ULN) and increases in total bilirubin (≥3 x ULN) is a marker for potential serious liver injury. Liver aminotransferase levels must be measured prior to initiation of treatment and then monthly. Avoid using Tracleer in patients with moderate or severe liver impairment or elevated ALT/AST >3 x ULN.

If clinically significant fluid retention develops, with or without associated weight gain, the cause, such as Tracleer or underlying heart failure, must be determined. Patients may require treatment or Tracleer therapy may need to be discontinued.

Preclinical data and an open-label safety study (N=25) showed a decline in sperm count of ≥50% in 25% of Tracleer-treated patients after 3 or 6 months. After 6 months, sperm count remained in normal range, with no changes in sperm morphology or motility, or hormone levels. Endothelin receptor antagonists such as Tracleer may adversely affect spermatogenesis.

Treatment with Tracleer can cause a dose-related decrease in hemoglobin (Hgb) and hematocrit. Hgb should be checked after 1 and 3 months, and then every 3 months. Upon marked decrease in Hgb, determine the cause and need for specific treatment.

If signs of pulmonary edema occur, the possibility of associated pulmonary veno-occlusive disease should be considered. Tracleer should be discontinued.

ADVERSE EVENTS
In Tracleer pivotal trials, the most common adverse events occurring more often in Tracleer-treated patients than in patients taking placebo (≥2%) were respiratory tract infection, edema, hypotension, sinusitis, arthralgia, liver function test abnormal, palpitations, and anemia.

Please see full Prescribing Information, including BOXED WARNING about liver injury and pregnancy.

Ventavis Indication:

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Ventavis Important Safety Information:

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information for Ventavis.